Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Medo AI
Singapore, Singapore
- Ownership
- Private
- Development stage
- Other
01
Overview
Medo AI developed an FDA-cleared, cloud-based AI platform that automates acquisition and interpretation of point-of-care ultrasound images, including segmentation and 3D visualization of anatomical structures, enabling novice users to diagnose common and critical conditions; at least two algorithms have obtained FDA clearance and are commercially deployed within Exo’s ultrasound ecosystem.[1][3][4][5][2]
- Therapeutic areas
- RheumatologyOther
- Modalities
- DeviceNon-pharmacological therapySoftware
- Industry
- Medical Imaging
02
Partnerships
Health systems and clinical partners in Asia and Canada for validation and adoption of Medo’s ultrasound AI technology[3]
Beyond the preview
Go deeper on Medo AI.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medo AI.